People · Operator
Named in public records as an officer, director or promoter · active 2008–2018 · Other, Other Health Care, Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Fluent, Inc. | — | Other | Series D+ | $264.9M | $97.2M | 2012 |
| Transenterix Inc. | — | Other Health Care | Series D+ | $209.9M | $21.9M | 2010 |
| Opko Health, Inc. | — | Pharmaceuticals | Series D+ | $206.0M | $6.2B | 2009 |
| Cocrystal Pharma, Inc. | — | Pharmaceuticals | Series A | $28.9M | $92.9M | 2016 |
| PROLOR Biotech, Inc. | — | Biotechnology | Series B | $26.4M | $968.4M | 2009 |
| Cocrystal Discovery Inc | — | Biotechnology | Series A | $15.2M | $271.1M | 2008 |
| Castle Brands Inc | — | Other | Series A | $11.1M | $18.9M | 2009 |
| Dreams Inc | — | Other | Seed | $2.0M | $4.0M | — |
| Non Invasive Monitoring Systems Inc /Fl/ | — | Other Health Care | Pre-Seed | $501K | $15.4M | 2013 |
Steven D. Rubin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Steven D. Rubin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.